Research programme: rheumatoid arthritis therapy - Wyeth

Drug Profile

Research programme: rheumatoid arthritis therapy - Wyeth

Alternative Names: B-cell depletion therapies; Calicheamicin-anti-CD22 MAb conjugate; CD22/Cal

Latest Information Update: 10 Aug 2009

Price : $50

At a glance

  • Originator Wyeth
  • Class Aminoglycosides; Enediynes; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action CD22 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 10 Aug 2009 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
  • 13 Jun 2005 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top